1. Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease.
- Author
-
Shen W, Chen X, Zhou L, Cheng Y, Zhang Y, Jiang X, Sun H, and Shen J
- Subjects
- Humans, Structure-Activity Relationship, Protease Inhibitors pharmacology, Protease Inhibitors chemistry, Protease Inhibitors chemical synthesis, Drug Discovery, COVID-19 virology, Molecular Structure, Coronavirus 3C Proteases antagonists & inhibitors, Coronavirus 3C Proteases metabolism, SARS-CoV-2 drug effects, Antiviral Agents pharmacology, Antiviral Agents chemical synthesis, Antiviral Agents chemistry, Acrylates pharmacology, Acrylates chemistry, Acrylates chemical synthesis
- Abstract
COVID-19 has caused severe consequences in terms of public health and economy worldwide since its outbreak in December 2019. SARS-CoV-2 3C-like protease (3CL
pro ), crucial for the viral replications, is an attractive target for the development of antiviral drugs. In this study, several kinds of Michael acceptor warheads were utilized to hunt for potent covalent inhibitors against 3CLpro . Meanwhile, novel 3CLpro inhibitors with the P3-3,5-dichloro-4-(2-(dimethylamino)ethoxy)phenyl moiety were designed and synthesized which may form salt bridge with residue Glu166. Among them, two compounds 12b and 12c exhibited high inhibitory activities against SARS-CoV-2 3CLpro . Further investigations suggested that 12b with an acrylate warhead displayed potent activity against HCoV-OC43 (EC50 = 97 nM) and SARS-CoV-2 replicon (EC50 = 45 nM) and low cytotoxicity (CC50 > 10 μM) in Huh7 cells. Taken together, this study devised two series of 3CLpro inhibitors and provided the potent SARS-CoV-2 3CLpro inhibitor (12b) which may be used for treating coronavirus infections., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Ltd.)- Published
- 2024
- Full Text
- View/download PDF